| Trump administration to pay 2 more companies to walk away from US offshore wind leases |
AP Online |
04/27 |
19:16 |
| Crypto News: AlphaPepe Presale Crosses $980k Raised as Ethereum Price Prediction Targets $7,500 Amid Massive ETF Inflows |
Globe Newswire |
04/27 |
19:00 |
| Sabres are on the verge of a long-awaited series win, and the Ducks are too |
AP Online |
04/27 |
18:54 |
| MINILUXE REPORTS FULL-YEAR FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 28, 2025 |
Globe Newswire |
04/27 |
18:52 |
| Sabalenka avoids Madrid Open virus scare and Osaka upset. Gauff and Rybakina lose |
AP Online |
04/27 |
18:46 |
| ROSEN, LEADING INVESTOR COUNSEL, Encourages Upstart Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – UPST |
Globe Newswire |
04/27 |
18:43 |
| ROSEN, A LEADING LAW FIRM, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - LU |
Globe Newswire |
04/27 |
18:41 |
| HTGC Investor Alert: Hercules Capital Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Valuation Diligence: Levi & Korsinsky |
Globe Newswire |
04/27 |
18:39 |
| GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing to Disclose Trial Risks: Levi & Korsinsky |
Globe Newswire |
04/27 |
18:33 |
| Five Star Bancorp Announces First Quarter 2026 Results |
Globe Newswire |
04/27 |
18:30 |
| CWH Investor Alert: Camping World Holdings, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Wagner Allegedly Misrepresented Demand Trends: Levi & Korsinsky |
Globe Newswire |
04/27 |
18:21 |
| ROSEN, LEADING TRIAL ATTORNEYS, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important May 11 Deadline in Securities Class Action First Filed by the Firm - TCOM |
Globe Newswire |
04/27 |
18:12 |
| NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm |
Globe Newswire |
04/27 |
18:02 |
| Rubicon Organics to Report Q1 2026 Results; Announces Line of Credit Amendment |
Globe Newswire |
04/27 |
18:00 |
| Clinical Man United beats Brentford to move clear in third place |
AP Online |
04/27 |
17:59 |
| Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline |
Globe Newswire |
04/27 |
17:58 |
| COTY Investor Alert: Coty Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Slowing Growth: Levi & Korsinsky |
Globe Newswire |
04/27 |
17:58 |
| Texas Tech QB Brendan Sorsby enters treatment program for a gambling addiction following transfer |
AP Online |
04/27 |
17:47 |
| ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights |
Globe Newswire |
04/27 |
17:47 |
| NOV Reports First Quarter 2026 Earnings |
Globe Newswire |
04/27 |
17:45 |
| ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vital Farms, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - VITL |
Globe Newswire |
04/27 |
17:44 |
| BW Investor Alert: Babcock & Wilcox Enterprises Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Pipeline Metrics: Levi & Korsinsky |
Globe Newswire |
04/27 |
17:42 |
| Performance Shipping Inc. Announces Filing of 2025 Annual Report on Form 20-F |
Globe Newswire |
04/27 |
17:39 |
| ROSEN, A NATIONALLY RECOGNIZED INVESTOR RIGHTS LAW FIRM, Encourages Hercules Capital, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– HTGC |
Globe Newswire |
04/27 |
17:38 |
| Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment |
Globe Newswire |
04/27 |
17:37 |
